Login / Signup

Pentoxifylline as a Novel Add-on Therapy for Major Depressive Disorder in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.

Talar A Merza MohammadTavgah A Merza MohammadDyar M SalmanHalmat M Jaafar
Published in: Pharmacopsychiatry (2024)
These findings support the safety and efficacy of PTX as an adjunctive antidepressant agent with anti-inflammatory effects in patients with MDD.
Keyphrases
  • major depressive disorder
  • double blind
  • placebo controlled
  • bipolar disorder
  • clinical trial
  • phase iii
  • study protocol
  • phase ii
  • randomized controlled trial